O Schmitz, S Lund, PH Andersen, M Jønler, N … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—The study was a double-blind, randomized,
parallel-group trial in 19 antidiabetic agent-naive subjects with type 2
diabetes (mean age 58 years, known duration of diabetes 3.5 years, HbA 1c ... Cited by 23 - Related articles - BL Direct - All 5 versions
RG Moses, R Gomis, KB Frandsen, JL … - Diabetes Care, 2001 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS— A total of 408 patients with type 2 diabetes
considered poorly controlled by diet, but without a history of previous
antidiabetic medication, were randomized to receive 0.5 mg repaglinide at ... Cited by 48 - Related articles - BL Direct - All 7 versions
S Madsbad, B Kilhovd, I Lager, P Mustajoki, A … - Diabetic Medicine, 2001 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 30 - Related articles - BL Direct - All 6 versions
AJ Garber - medi.ru Диабет II типа характеризуется
прогрессирующим ухудшением прандиальной
секреции инсулина на фоне существующей ... Related articles - Cached - All 2 versions
R Landgraf, M Frank, C Bauer, ML Dieken - International journal of obesity and related metabolic …, 2000 - ncbi.nlm.nih.gov OBJECTIVE: Prandial glucose regulation has the potential for achieving good
metabolic control with a low risk of hypoglycaemia and increased flexibility
with regard to eating patterns. Comparative studies have suggested that the ... Cited by 38 - Related articles - BL Direct - All 3 versions
- ►landspitali.is [PDF] K Kølendorf, J Eriksson, KI Birkeland, T … - Diabetes research and clinical practice, 2004 - Elsevier A total of 385 drug-therapy naïve patients, with inadequately controlled type 2
diabetes, were randomised into a multinational, parallel-group study to compare
two strategies for dose titration of the oral hypoglycaemic agent ... Related articles - All 13 versions
R Moses - eop, 2000 - Informa Pharma Science Repaglinide is a novel insulin secretagogue that was developed as a prandial
glucose regulator for the treatment of people with Type 2 diabetes mellitus. It
is used flexibly, taken prior to meals, in order to limit subsequent ... Cited by 24 - Related articles - All 4 versions
